Does gynaecomastia cause nipple discharge? It is a question that concerns many men who notice changes in their breast tissue. Gynaecomastia — the benign enlargement of glandular breast tissue in males — does not directly cause nipple discharge, but the two can occur together when a shared underlying hormonal or pharmacological trigger is present. Understanding the distinction between gynaecomastia and nipple discharge, what causes each, and when to seek medical advice is essential for prompt, appropriate care. This article explains the relationship clearly, using current NHS and NICE guidance.

What Is Gynaecomastia and How Does It Affect Breast Tissue

Gynaecomastia is benign glandular breast enlargement in males due to oestrogen-androgen imbalance; it does not directly cause nipple discharge, but shared hormonal causes such as hyperprolactinaemia can produce both simultaneously.

Gynaecomastia is the benign enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and androgen activity within the breast. It can affect one or both breasts and is relatively common, occurring at various life stages including puberty, middle age, and older adulthood. The condition is distinct from pseudogynaecomastia, which refers to fatty tissue accumulation without true glandular proliferation.

In terms of whether gynaecomastia directly causes nipple discharge, the answer is nuanced. Gynaecomastia itself — the glandular enlargement — does not typically produce nipple discharge as a direct symptom. The hormonal environment that drives gynaecomastia can, however, independently stimulate ductal tissue and potentially lead to discharge. Crucially, it is elevated prolactin (hyperprolactinaemia) — rather than oestrogen excess alone — that is the principal endocrine driver of milky nipple discharge (galactorrhoea) in men. Oestrogen excess alone rarely causes nipple discharge in cisgender men. It is therefore most accurate to say that shared underlying hormonal or pharmacological causes may produce both gynaecomastia and nipple discharge simultaneously, rather than one directly causing the other.

The glandular tissue in gynaecomastia undergoes ductal proliferation and stromal changes, which can make the breast more sensitive and occasionally tender. Where prolactin is elevated — for example, due to a pituitary adenoma or a dopamine-antagonist medicine — milky discharge may occur alongside breast enlargement. This distinction is clinically important, as it points towards a systemic hormonal or pharmacological cause rather than a localised breast problem.

Any nipple discharge in men is not a normal finding and should always be evaluated promptly. While benign explanations exist, discharge can occasionally signal an underlying condition requiring further investigation. (NICE CKS: Gynaecomastia; NHS: Gynaecomastia — male breast enlargement)

Other Causes of Nipple Discharge in Men

Nipple discharge in men is uncommon and can result from hyperprolactinaemia, medications, ductal ectasia, intraductal papilloma, or — rarely — male breast cancer, which must always be excluded.

Nipple discharge in men is uncommon and, when present, warrants careful assessment. There are several potential causes beyond the hormonal overlap with gynaecomastia, and identifying the correct aetiology guides appropriate management.

Common and notable causes include:

• Hyperprolactinaemia — Elevated prolactin levels, most often due to a pituitary adenoma (prolactinoma) or a dopamine-antagonist medicine, are the commonest endocrine cause of milky nipple discharge in men. This is one of the most clinically significant causes and requires blood testing and imaging.

• Medications — A wide range of drugs can elevate prolactin or alter sex hormone balance. Examples relevant in UK practice include: antipsychotics (e.g., haloperidol, risperidone, olanzapine), metoclopramide, domperidone, spironolactone, finasteride, anti-androgens (e.g., bicalutamide), GnRH analogues, SSRIs, tricyclic antidepressants, cimetidine, verapamil, opioids, and some antiretrovirals. Cannabis use has also been associated with gynaecomastia. Medication-induced discharge often resolves upon cessation or substitution of the causative agent, but this should only be done under medical supervision. Patients who suspect a medicine is causing their symptoms should report it via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

• Ductal ectasia — Widening and inflammation of the milk ducts can produce a thick, sometimes coloured discharge. This is a benign condition but should be distinguished from more serious pathology.

• Periductal mastitis and subareolar abscess — Infection or inflammation around the ducts can cause discharge, pain, and swelling. Smoking is a recognised risk factor.

• Intraductal papilloma — A benign growth within a breast duct that can cause clear or blood-stained discharge.

• Breast cancer — Although rare in men (accounting for less than 1% of all breast cancers in the UK), male breast cancer can present with unilateral, blood-stained, or persistent nipple discharge. Spontaneous, unilateral, or blood-stained discharge in men has a higher likelihood of an underlying pathological cause, including malignancy, and warrants urgent assessment. This must always be excluded.

• Systemic conditions — Liver disease, renal failure, and thyroid dysfunction can all disrupt hormone metabolism and contribute to both gynaecomastia and discharge. Testicular or adrenal tumours producing hCG or oestrogen are also important to consider.

Pseudogynaecomastia (fatty tissue without glandular proliferation) is not associated with nipple discharge. The presence of discharge alongside breast changes should always prompt a structured clinical review. (NICE CKS: Gynaecomastia; NHS: Breast cancer in men)

When to Seek Medical Advice About Nipple Discharge

Men should contact their GP promptly for any spontaneous, blood-stained, or persistent nipple discharge; NICE NG12 recommends urgent two-week-wait referral for men aged 50 and over with unilateral nipple discharge.

Men who notice nipple discharge should seek medical advice promptly. It is not a normal finding and can indicate an underlying condition that requires assessment. Do not wait to see whether it resolves on its own — early review is always recommended.

Important: Avoid squeezing or expressing the nipple before your appointment, as this can stimulate further discharge and make assessment more difficult.

Contact your GP as soon as possible if you experience:

• Any spontaneous nipple discharge (i.e., discharge that occurs without squeezing or stimulation)

• Blood-stained or dark-coloured discharge from one or both nipples

• Discharge accompanied by a lump, skin changes, or nipple inversion

• Persistent discharge of any kind

• Discharge alongside breast pain, swelling, or tenderness

• Any breast changes combined with symptoms such as headaches, visual disturbances, or reduced libido (which may suggest a pituitary problem)

Milky discharge in men, particularly when bilateral and associated with breast enlargement, may suggest hyperprolactinaemia and should be assessed without delay. Unilateral discharge — especially if blood-stained or spontaneous — raises the possibility of an intraductal lesion or, in rare cases, malignancy.

In line with NICE NG12 (Suspected Cancer: Recognition and Referral), GPs should refer men aged 50 and over with unilateral nipple discharge, nipple retraction, or other unexplained nipple changes via the urgent suspected cancer (two-week wait) pathway. Men aged 30 and over with an unexplained breast lump should also be referred urgently. Prompt referral does not mean cancer has been diagnosed — it ensures timely specialist assessment and appropriate reassurance where findings are benign.

Patients currently taking medicines known to affect prolactin levels should inform their GP, as a medication review may be an important first step. Do not stop any prescribed medicine without medical advice. (NICE NG12; NHS: Breast cancer in men)

Diagnosis and Assessment on the NHS

GP assessment includes history, examination, blood tests (prolactin, testosterone, beta-hCG, LH, FSH), and referral to a breast clinic or endocrinology service if malignancy or a pituitary lesion is suspected.

When a man presents to his GP with nipple discharge — with or without gynaecomastia — a structured assessment is undertaken to identify the underlying cause. NICE guidance and NHS clinical pathways support a systematic approach to breast symptoms in men, recognising that whilst male breast conditions are less common, they require the same clinical rigour as in women.

The initial GP assessment typically includes:

• A detailed history — including the nature, colour, and duration of discharge; whether it is spontaneous or expressed; associated symptoms; full medication history; alcohol and cannabis use; and any relevant systemic conditions

• Physical examination — assessing both breasts for glandular tissue, lumps, skin changes, and nipple abnormalities, alongside examination of the testes where clinically indicated

• Blood tests — including serum prolactin, testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, beta-hCG (to exclude hCG-secreting germ cell tumours), liver function tests, renal function, and thyroid function

• Scrotal ultrasound — considered where testicular pathology or a germ cell tumour is suspected as a cause of endocrine disturbance

• Referral to secondary care — if there is clinical suspicion of malignancy, a pituitary lesion, or unexplained persistent discharge, the GP will refer to a breast clinic or endocrinology service

At the breast clinic, further investigations may include:

• Breast ultrasound — typically the first-line imaging modality in men

• Mammography — added as clinically indicated

• MRI of the breast — considered if persistent pathological discharge is present with negative conventional imaging

• MRI of the pituitary gland — arranged if a pituitary adenoma is suspected based on elevated prolactin

• Ductography — not a first-line investigation in UK practice; considered selectively in specific cases

Nipple discharge cytology is not routinely recommended due to its low diagnostic sensitivity and yield.

In line with NICE NG12, men aged 50 and over with unilateral nipple discharge or other unexplained nipple changes, and men aged 30 and over with an unexplained breast lump, should be referred urgently via the two-week wait pathway to exclude breast cancer. (NICE NG12; NICE CKS: Gynaecomastia; Association of Breast Surgery UK guidance)

Treatment Options and Next Steps

Treatment is tailored to the underlying cause and may include dopamine agonist therapy for prolactinoma, medication review, antibiotics for ductal infection, or surgery for persistent symptomatic gynaecomastia.

Treatment for nipple discharge in men depends entirely on the underlying cause identified during assessment. There is no single universal treatment, and management is tailored to the individual based on clinical findings, investigation results, and the impact on quality of life.

Where a medicine is identified as the cause, the prescribing clinician will review whether the drug can be stopped, reduced in dose, or substituted with an alternative that carries a lower risk of prolactin elevation or hormonal disruption. This should never be done without medical supervision — particularly for antipsychotic medicines, where abrupt cessation can carry significant risks. If you suspect a medicine is causing your symptoms, report it via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

For hyperprolactinaemia due to a prolactinoma, treatment typically involves dopamine agonist therapy — most commonly cabergoline (first-line) or bromocriptine — which reduces prolactin levels and often shrinks the adenoma. These are prescribed and monitored by an endocrinologist. Surgical intervention is rarely required but may be considered in specific cases.

For benign ductal conditions such as ductal ectasia or intraductal papilloma, management may involve watchful waiting, antibiotics if infection is present, or minor surgical excision of the affected duct if discharge is persistent or troublesome. For periductal mastitis, treatment includes antibiotics, drainage of any abscess, and — where relevant — smoking cessation advice, as smoking is a recognised risk factor.

For gynaecomastia itself, treatment options include:

• Observation — particularly in adolescent boys, where the condition often resolves spontaneously within one to two years

• Medication review — addressing any causative drugs

• Hormonal therapy — short-term use of tamoxifen (a SERM) may be considered under specialist supervision for symptomatic gynaecomastia. It is important to note that this use is off-label in the UK. Anastrozole (an aromatase inhibitor) has limited evidence of benefit in men and is not routinely recommended for gynaecomastia in UK practice; its use would also be off-label. Any such treatment should only be initiated and monitored by a specialist.

• Surgery — subcutaneous mastectomy may be offered for persistent, symptomatic gynaecomastia that has not responded to other measures

If breast cancer is diagnosed, treatment follows established NHS oncology pathways including surgery, radiotherapy, and systemic therapy as appropriate.

The key message for patients is that seeking early medical advice leads to faster diagnosis, more treatment options, and better outcomes — whatever the underlying cause. (NICE CKS: Gynaecomastia; EMC SmPCs: cabergoline, bromocriptine, tamoxifen, anastrozole; MHRA Yellow Card Scheme)

Frequently Asked Questions